Medpace reported strong fourth quarter and full year 2025 results, with Q4 revenue increasing 32% year-over-year to $708.5 million and full-year revenue reaching $2.53 billion, a 20% increase. EBITDA for the quarter rose 20% to $160.2 million, though margins compressed to 22.6% due to a higher mix of reimbursable costs from metabolic programs. A key concern was elevated cancellations in Q4, the highest in over a year, which resulted in a net book-to-bill ratio of 1.04. For 2026, management guides for revenue growth of 8.9% to 12.8% and EBITDA growth of 8.5% to 13.9%, assuming a normalization of cancellations and continued productivity gains from improved retention.
| Metric | Value | Change |
|---|---|---|
| Q4 Revenue | $708.5 million | +32% |
| FY 2025 Revenue | $2.53 billion | +20% |
| Q4 EBITDA | $160.2 million | +20% |
| FY 2025 EBITDA | $557.7 million | +16.1% |
| Q4 Net Income | $135.1 million | +15.5% |
| FY 2025 EPS | $15.28 | +21.1% |
| Ending Backlog | $3.0 billion | +4.3% |
| Net Book-to-Bill | 1.04 | N/A |
| Q4 EBITDA Margin | 22.6% | -230 bps |
Management emphasized that the high level of reimbursable costs (pass-throughs) in 2025 was driven by metabolic programs, specifically obesity and diabetes. They expect this mix to normalize in 2026, with pass-throughs starting the year higher and ending lower. This normalization creates a headwind to reported revenue growth but improves the quality of revenue (more direct fees) and should alleviate some margin pressure experienced in late 2025.
A key strategic lever for Medpace is improved employee retention. By retaining more staff, Medpace reduces training costs and increases utilization, allowing them to grow revenue faster than headcount. Management anticipates hiring in the mid-to-high single digits for 2026, which is lower than the expected revenue growth rate, signaling continued productivity gains.
Medpace is taking a 'measured' approach to Artificial Intelligence. While rolling out tools for efficiency and data analytics in 2026, the CEO expects investment costs to match benefits initially. He views AI as a potential long-term net negative for service revenue if it reduces the need for staff, though he believes it will encourage more drug development overall.
The company continues to aggressively return capital to shareholders. In 2025, Medpace repurchased $912.9 million worth of shares. With $821.7 million remaining under its authorization and nearly $500 million in cash, the company has significant capacity for further buybacks, which supports EPS growth even as revenue growth moderates.
The most significant red flag is the spike in cancellations, which were the 'highest they have been in over a year.' Management could not pinpoint a specific cause, attributing it to 'random stuff' and noting it was widespread rather than concentrated in a few clients. This lack of visibility makes the 1.04 book-to-bill and future backlog conversion harder to model with high confidence.
EBITDA margins declined in both Q4 (22.6% vs 24.9%) and FY 2025 (22% vs 22.8%). Management attributes this to the therapeutic mix (high pass-throughs). While they expect margins to stabilize in 2026, the current trend suggests the high-growth metabolic segment is less profitable than legacy business, creating a margin headwind as long as the mix remains elevated.
2026 guidance implies a significant slowdown in revenue growth to approximately 9-13% from 20% in 2025. While partly due to the tough comparison against the metabolic boom, it signals that the hyper-growth phase may be moderating. Additionally, the guidance assumes 'normal' cancellation rates, which creates risk if the elevated Q4 trend persists.
CEO August Troendle explicitly stated that AI could be a 'net negative to a service company' in the long run by reducing the staff hours needed, thereby reducing revenue. While he believes this will take years to materialize, it highlights a structural risk to the labor-based CRO model that investors must monitor.
Overall: Management maintained a pragmatic and transparent tone throughout the call. CEO August Troendle was direct about the 'elevated' cancellations and the 'adequate' business environment, avoiding excessive optimism while reinforcing confidence in the company's positioning. CFO Kevin Brady provided detailed financial context, particularly regarding the impact of pass-through costs on margins.
Confidence: MEDIUM - Management expressed confidence in the 2026 guidance and the fundamental demand drivers, citing 'good' RFP activity and 'strong' funding. However, confidence was tempered by the inability to pinpoint the specific cause of the cancellation spike, with Troendle admitting he 'did not anticipate the spike in Q4' and that 'only time will tell' if it persists.
$2.755 billion to $2.855 billion (+8.9% to +12.8%)
$605 million to $635 million (+8.5% to +13.9%)
$487 million to $511 million
$16.68 to $17.50
18.5% to 19.5%
Hedging & Uncertainty: Management employed hedging language primarily around the cancellation anomaly and the business environment. Phrases like 'Only time will tell' and 'I see no reason to expect... but did not anticipate' indicate uncertainty about the immediate future. The CEO used the word 'adequate' to describe the business environment, which is notably less enthusiastic than 'strong' or 'robust,' suggesting a cautious outlook. Regarding AI, they hedged on the timeline ('too early to know', 'years') and the net benefit ('investment is going to at least equal the benefits').
I rate the overall business environment as adequate and headed in the right direction. - August Troendle, CEO
Cancellations were elevated again in Q4... highest they have been in over a year. - August Troendle, CEO
I do not anticipate really any productivity advantage... in 2026. - August Troendle, CEO
It's just not something that we do. - Kevin Brady, CFO
I think it's too early to know what kind of changes. - August Troendle, CEO
Analyst Sentiment: Analysts were laser-focused on the cancellation anomaly, asking multiple questions to determine if it was a funding issue, competitive pressure, or specific to the metabolic therapeutic area. There was also skepticism regarding the sustainability of margins given the high pass-through mix and the deceleration in growth.
Management Responses: Management remained consistent, reiterating that cancellations were 'widespread' and 'random' rather than systemic. They pushed back on the idea that the competitive landscape had changed or that AI would impact 2026 results. They deflected questions about specific burn rates and gross booking metrics, focusing instead on the 'adequate' environment and productivity gains.
Analysts pressed heavily on the root cause of elevated cancellations, specifically asking if they were driven by funding issues, M&A, or clinical failures. Management clarified they were widespread and not due to one client, but admitted to no clear pattern.
There was significant discussion regarding 'pass-through' costs and their impact on margins. Analysts sought to understand if the high pass-throughs were a permanent feature of the metabolic business or a temporary headwind.
Questions regarding AI focused on whether it would disrupt the CRO model. Management downplayed the immediate impact, framing it as a long-term uncertainty where investment currently offsets productivity gains.
Medpace remains a best-in-class CRO with strong operational execution and robust capital returns. However, the Q4 earnings call introduces near-term uncertainty. The spike in cancellations—unexplained and widespread—combined with the guidance for slower growth in 2026, suggests the company is transitioning out of a hyper-growth phase driven by the metabolic boom. While the 2026 guidance implies stability, the margin pressure and 'adequate' macro commentary warrant a HOLD rating until the cancellation trend normalizes and the metabolic mix stabilizes.
Management noted a 'pretty good funding quarter' and stated RFPs were up, suggesting the capital markets freeze for biotech has thawed compared to prior years.
An 'accelerating M&A environment' where large pharma buys biotech clients is occurring. Management views this as a long-term risk (losing the client identity) but not a short-term revenue risk.
AI is viewed as a double-edged sword; it may drive more drug development (positive) but could reduce the labor intensity of trials (negative for CRO revenue).